IP Library Granted Patent US 7,737,138
Granted Patent B2
US 7,737,138 · App. 11/391,675 · Granted Jun 15, 2010

Methods of treatment of a tauopathy condition comprising the use of thioninium compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,737,138
App. No.
11/391,675
Granted
Jun 15, 2010
Kind
B2
Abstract

This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diaminophenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.

Claims (34)

1. A method of treatment of Alzheimer's disease (AD) in a patient, comprising administering to said patient a compound selected from the following compounds:

(A) ethyl-thioninium chloride (ETC),

(B) 1,9-diethyl-methyl-thioninium chloride (DEMTC),

(C) 1,9-dimethyl-ethyl-thioninium chloride (DMETC),

(D) 1,9-diethyl-ethyl-thioninium chloride (DEETC),

(F) ethyl-thioninium chloride zinc chloride mixed salt (ETZ),

(I) ethyl-thioninium iodide (ETI),

(J) ethyl-thioninium iodide hydrogen iodide mixed salt (ETI.HI),

(L) ethyl-thioninium nitrate (ETN).

2. A method according to claim 1 , wherein the compound is (A) ethyl-thioninium chloride (ETC).

3. A method according to claim 1 , wherein the compound is (B) 1,9-diethyl-methyl-thioninium chloride (DEMTC).

4. A method according to claim 1 , wherein the compound is (C) 1,9-dimethyl-ethyl-thioninium chloride (DMETC).

5. A method according to claim 1 , wherein the compound is (D) 1,9-diethyl-ethyl-thioninium chloride (DEETC).

6. A method according to claim 1 , wherein the compound is (F) ethyl-thioninium chloride zinc chloride mixed salt (ETZ).

7. A method according to claim 1 , wherein the compound is (I) ethyl-thioninium iodide (ETI).

8. A method according to claim 1 , wherein the compound is (J) ethyl-thioninium iodide hydrogen iodide mixed salt (ETI.HI).

9. A method according to claim 1 , wherein the compound is (L) ethyl-thioninium nitrate (ETN).

10. A method of treatment of Alzheimer's disease (AD), Pick's disease, Progressive Supranuclear Palsy (PSP), fronto-temporal dementia (FTD), parkinsonism linked to chromosome 17 (FTDP-17), disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC), pallido-ponto-nigral degeneration (PPND), Guam-ALS syndrome, pallido-nigro-luysian degeneration (PNLD), or cortico-basal degeneration (CBD) in a patient, comprising administering to said patient a compound selected from the following compounds:

(A) ethyl-thioninium chloride (ETC),

(B) 1,9-diethyl-methyl-thioninium chloride (DEMTC),

(C) 1,9-dimethyl-ethyl-thioninium chloride (DMETC),

(D) 1,9-diethyl-ethyl-thioninium chloride (DEETC),

(F) ethyl-thioninium chloride zinc chloride mixed salt (ETZ),

(I) ethyl-thioninium iodide (ETI),

(J) ethyl-thioninium iodide hydrogen iodide mixed salt (ETI.HI),

(L) ethyl-thioninium nitrate (ETN).

11. A method according to claim 10 , wherein the compound is (A) ethyl-thioninium chloride (ETC).

12. A method according to claim 10 , wherein the compound is (B) 1,9-diethyl-methyl-thioninium chloride (DEMTC).

13. A method according to claim 10 , wherein the compound is (C) 1,9-dimethyl-ethyl-thioninium chloride (DMETC).

14. A method according to claim 10 , wherein the compound is (D) 1,9-diethyl-ethyl-thioninium chloride (DEETC).

15. A method according to claim 10 , wherein the compound is (F) ethyl-thioninium chloride zinc chloride mixed salt (ETZ).

16. A method according to claim 10 , wherein the compound is (I) ethyl-thioninium iodide (ETI).

17. A method according to claim 10 , wherein the compound is (J) ethyl-thioninium iodide hydrogen iodide mixed salt (ETI.HI).

18. A method according to claim 10 , wherein the compound is (L) ethyl-thioninium nitrate (ETN).

Assignments (4)
CHANGE OF ADDRESS Recorded Jan 20, 2015
From: WISTA LABORATORIES LTD.
To: WISTA LABORATORIES LTD.
Reel/Frame 034781/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2007
From: UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE
To: TAURX THERAPEUTICS LTD
Reel/Frame 018842/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2007
From: WISCHIK, CLAUDE MICHEL; RICKARD, JANET ELIZABETH; HARRINGTON, CHARLES ROBERT; HORSLEY, DAVID; STOREY, JOHN MERVYN DAVID; MARSHALL, COLIN; SINCLAIR, JAMES PETER; TAN, HAN WAN
To: UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE
Reel/Frame 018842/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2007
From: TAURX THERAPEUTICS LTD
To: WISTA LABORATORIES LTD
Reel/Frame 018845/0029 →